| Influenza vaccine indication during therapy with immune checkpoint inhibitors: a transversal challenge. The INVIDIa study M Bersanelli, D Giannarelli, P Castrignanò, G Fornarini, S Panni, ... Immunotherapy 10 (14), 1229-1239, 2018 | 50 | 2018 |
| Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study G Procopio, G Apollonio, F Cognetti, R Miceli, M Milella, A Mosca, ... European urology oncology 2 (6), 699-707, 2019 | 48 | 2019 |
| KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer DP Petrylak, R Ratta, R Gafanov, G Facchini, JM Piulats, G Kramer, ... Future Oncology 17 (25), 3291-3299, 2021 | 46 | 2021 |
| PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review R Ratta, A Guida, F Scotté, Y Neuzillet, AB Teillet, T Lebret, P Beuzeboc Prostate Cancer and Prostatic Diseases 23 (4), 549-560, 2020 | 41 | 2020 |
| Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population G Peverelli, A Raimondi, R Ratta, E Verzoni, M Bregni, E Cortesi, ... Clinical Genitourinary Cancer 17 (4), 291-298, 2019 | 37 | 2019 |
| Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program G Procopio, M Prisciandaro, R Iacovelli, E Cortesi, G Fornarini, G Facchini, ... Clinical Genitourinary Cancer 16 (4), e945-e951, 2018 | 37 | 2018 |
| Analysis of single circulating tumor cells in renal cell carcinoma reveals phenotypic heterogeneity and genomic alterations related to progression V Cappelletti, E Verzoni, R Ratta, M Vismara, M Silvestri, R Montone, ... International journal of molecular sciences 21 (4), 1475, 2020 | 36 | 2020 |
| Angiogenesis and immunity in renal carcinoma: can we turn an unhappy relationship into a happy marriage? A Mennitto, V Huber, R Ratta, P Sepe, F de Braud, G Procopio, ... Journal of clinical medicine 9 (4), 930, 2020 | 35 | 2020 |
| Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis D Santini, R Ratta, F Pantano, D De Lisi, M Maruzzo, L Galli, E Biasco, ... Oncotarget 8 (59), 100708, 2017 | 35 | 2017 |
| Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience A Mennitto, P Grassi, R Ratta, E Verzoni, M Prisciandaro, G Procopio Therapeutic Advances in Urology 8 (5), 319-326, 2016 | 32 | 2016 |
| Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients B Vincenzi, A Zoccoli, G Schiavon, M Iuliani, F Pantano, E Dell’Aquila, ... European journal of cancer 49 (6), 1501-1508, 2013 | 28 | 2013 |
| Multimodal treatment of advanced renal cancer in 2017 A Mennitto, E Verzoni, P Grassi, R Ratta, G Fucà, G Procopio Expert review of clinical pharmacology 10 (12), 1395-1402, 2017 | 27 | 2017 |
| Immunotherapy advances in uro-genital malignancies R Ratta, R Zappasodi, D Raggi, P Grassi, E Verzoni, A Necchi, ... Critical Reviews in Oncology/Hematology 105, 52-64, 2016 | 27 | 2016 |
| Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an Italian managed access program M Prisciandaro, R Ratta, F Massari, G Fornarini, S Caponnetto, R Iacovelli, ... American journal of clinical oncology 42 (1), 42-45, 2019 | 25 | 2019 |
| Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study S Buti, M Bersanelli, A Viansone, A Leonetti, C Masini, R Ratta, ... Cancer Treatment and Research Communications 22, 100161, 2020 | 24 | 2020 |
| Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients V Conteduca, O Caffo, L Fratino, G Lo Re, U Basso, A D’Angelo, M Donini, ... Future Oncology 11 (21), 2881-2891, 2015 | 23 | 2015 |
| Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. DP Petrylak, R Ratta, N Matsubara, EP Korbenfeld, R Gafanov, L Mourey, ... Journal of Clinical Oncology 41 (6_suppl), 19-19, 2023 | 22 | 2023 |
| Side effects of immunotherapy: a constant challenge for oncologists F Scotté, R Ratta, P Beuzeboc Current Opinion in Oncology 31 (4), 280-285, 2019 | 22 | 2019 |
| Safety and clinical outcomes of abiraterone acetate after docetaxel in octogenarians with metastatic castration-resistant prostate cancer: results of the Italian compassionate … F Maines, O Caffo, U De Giorgi, L Fratino, GL Re, V Zagonel, A D'Angelo, ... Clinical Genitourinary Cancer 14 (1), 48-55, 2016 | 22 | 2016 |
| Combination of baseline LDH, performance status and age as integrated algorithm to identify solid tumor patients with higher probability of response to anti PD-1 and PD-L1 … MS Cona, M Lecchi, S Cresta, S Damian, M Del Vecchio, A Necchi, ... Cancers 11 (2), 223, 2019 | 21 | 2019 |